摘要
目的:分析四联疗法和高剂量二联疗法对幽门螺杆菌根除率及复发率的影响。方法:回顾性分析2022年1—12月晋江市医院消化内科收治的100例幽门螺杆菌感染患者的临床资料,根据治疗方案,分为二联组(阿莫西林+伏诺拉生,n=37)、四联组(阿莫西林+多西环素+复方铝酸铋+艾司奥美拉唑,n=63)。对比分析两组的治疗总有效率、幽门螺杆菌根除率、1年内复发率及治疗前后炎症指标、症状积分,并统计对比两组的不良反应发生率。结果:两组治疗总有效率、幽门螺杆菌根除率比较,差异均无统计学意义(P>0.05);四联组1年内复发率显著低于二联组,不良反应发生率高于二联组,差异均有统计学意义(P<0.05)。治疗后,四联组各项炎症指标及症状积分均显著低于二联组,差异均有统计学意义(P<0.05)。结论:对于幽门螺杆菌感染患者而言,四联方案与二联方案各有优缺点,前者较之后者可更快消除疾病症状与炎症,并保障远期预后,而后者较前者具有更佳用药安全保证,在临床应用时,可根据患者疾病特点合理选择。
Objective:To analyze the effects of quadruple therapy and high-dose double therapy on the eradication rate and recurrence rate of Helicobacter pylori.Method:The clinical data of 100 patients with Helicobacter pylori infection admitted to the Department of Gastroenterology of Jinjiang Hospital from January to December 2022 were retrospectively analyzed.According to the treatment plan,they were divided into twocombination group(Amoxicillin+Vonorazan,n=37)and four-combination group(Amoxicillin+Doxicycline+Compound Bismuth Aluminum+Esomeprazole,n=63).The total effective rate,Helicobacter pylori eradication rate,recurrence rate within 1 year,inflammatory indicators and symptom scores before and after treatment were compared between the two groups,and the incidence of adverse reactions was compared between the two groups.Result:There were no significant differences in the total effective rate and eradication rate of Helicobacter pylori between the two groups(P>0.05).The recurrence rate within 1 year in the four-combination group was significantly lower than that in the two-combination group,and the incidence of adverse reactions was higher than that in the twocombination group,the differences were statistically significant(P<0.05).After treatment,the inflammatory indexes and symptom scores of the four-combination group were significantly lower than those of the two-combination group,the differences were statistically significant(P<0.05).Conclusion:For patients with Helicobacter pylori infection,the quadruple therapy and double therapy each have advantages and disadvantages.Compared with the latter,the former can eliminate disease symptoms and inflammation faster and guarantee long-term prognosis,while the latter has better drug safety guarantee than the former.In clinical application,reasonable selection can be made according to the disease characteristics of patients.
作者
黄惠文
王华秀
李夏薇
陈丽玲
HUANG Huiwen;WANG Huaxiu;LI Xiawei;CHEN Liling(Gastroenterology Department,Jinjiang Hospital,Jinjiang 362200,China;不详)
出处
《中国医学创新》
CAS
2024年第26期141-144,共4页
Medical Innovation of China
基金
晋江市医院(上海市第六人民医院福建医院)科技计划项目(2023LC05)。
作者简介
通信作者:黄惠文。
